Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 574
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT04086485 Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable … |
Lu-177-DOTATATE | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2022-10-03 → 2028-01-01 | Ouvrir |
| NCT06664034 Intervening on Women's Health for Rural Young Cancer Survivors |
Intervening on Women's Health for… | Cancer | Non applicable | COMPLETED | En attente / non publié | University of California, San Die… | United States · Cancer Resource Center of the Desert,… | 2024-12-01 → 2026-05-31 | Ouvrir |
| NCT02257736 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combinati… |
Apalutamide | Cancer | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Aragon Pharmaceuticals, Inc. | United States, Argentina, Australia, Belgium, Brazil,… | 2014-11-26 → 2027-12-31 | Ouvrir |
| NCT05896839 Immunotherapy in Combination With Prednisone and Sirolimus for Kidney T… |
Biopsy Procedure | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Emory University Hospital/Winship Can… | 2024-07-24 → 2027-01-31 | Ouvrir |
| NCT01087294 Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cell… |
Allogeneic stem cell transplant | Cancer | Phase 1 | COMPLETED | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2010-08-04 → 2024-04-02 | Ouvrir |
| NCT04538664 PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexe… |
Amivantamab | Cancer | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Janssen Research & Development, L… | United States, Australia, Belgium, Brazil, Canada, Ch… | 2020-10-13 → 2027-08-02 | Ouvrir |
| NCT05391321 EVAS-CCR — Identification of the Most Suitable Questionnaire to Assess … |
EVAS-CCR — Identification of the … | Cancer | Non applicable | COMPLETED | En attente / non publié | University Hospital, Limoges | France · Limoges university Hospital, Limoges, France | 2023-05-12 → 2025-01-07 | Ouvrir |
| NCT07795411 Prospective Multiomic Analysis in Small-Cell Lung Cancer |
Biospecimen Collection | Cancer | À vérifier | NOT_YET_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Ohio State University Comprehensive C… | 2026-11-25 → 2028-12-31 | Ouvrir |
| NCT05797246 Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) |
Bevacizumab | Cancer | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | AbbVie | United States · National Institutes of Health Clinica… | 2023-08-02 → 2029-01-01 | Ouvrir |
| NCT07789236 Mandala Coloring and Music for Cancer Fear and Screening Anxiety |
Mandala Coloring and Music for Ca… | Cancer | Non applicable | ENROLLING_BY_INVITATION | En attente / non publié | Agri Ibrahim Cecen University | Turkey (Türkiye) · Ağrı İbrahim Çeçen University, Ağr… | 2026-05-01 → 2026-12-30 | Ouvrir |
| NCT06398418 R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Pr… |
R-5780 | Cancer | Phase 1 | RECRUITING | En attente / non publié | Rise Therapeutics LLC | United States · Sarah Cannon Research Institute, Denv… | 2025-08-01 → 2027-12-31 | Ouvrir |
| NCT05298423 KEYVIBE-006 — Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combina… |
pembrolizumab/vibostolimab | Parkinson | Phase 3 | COMPLETED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Australia, Brazil, Chile, C… | 2022-05-03 → 2026-06-15 | Ouvrir |
| NCT07504198 Neuroprotection of Memantine and Rosuvastatin |
Memantine | Alzheimer | Phase 2/3 | NOT_YET_RECRUITING | En attente / non publié | NYU Langone Health | Egypt · Tanta, Tanta, Egypt | 2026-03 → 2027-05 | Ouvrir |
| NCT04165070 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (… |
Pembrolizumab | Parkinson | Phase 1/2 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Hungary, Israel, Italy, Poland, South … | 2019-12-19 → 2032-10-13 | Ouvrir |
| NCT05319730 A Study to Evaluate Investigational Agents With or Without Pembrolizuma… |
paclitaxel | Parkinson | Phase 1/2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States, Brazil, Chile, China, Germany, Italy, … | 2023-05-16 → 2029-04-10 | Ouvrir |
| NCT04165798 KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents W… |
Tumor Tissue Collection | Parkinson | À vérifier | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Hungary, Israel, Italy, Poland, South … | 2019-12-19 → 2032-02-13 | Ouvrir |
| NCT06780085 A Study of Investigational Agents in Participants With Previously Treat… |
Raludotatug Deruxtecan | Parkinson | Phase 2 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Chile, Germany, Greece, Hungary, Israe… | 2025-05-13 → 2032-03-12 | Ouvrir |
| NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epide… |
Pembrolizumab | Parkinson | Phase 3 | COMPLETED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Australia, Brazil, Chile, China, Franc… | 2018-10-05 → 2025-11-12 | Ouvrir |
| NCT03553485 Effects of VNS on RT-induced Inflammation and Prognosis of Patients Wit… |
transcutaneous vagus nerve stimul… | SEP | Non applicable | UNKNOWN | En attente / non publié | Kyoungwon Baik | Belgium · UZ Brussels, Brussels, Belgium | 2018-08-08 → 2019-12 | Ouvrir |
| NCT06627647 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemoth… |
Rilvegostomig | Cancer | Phase 3 | RECRUITING | En attente / non publié | AstraZeneca | United States, Argentina, Australia, Belgium, Brazil,… | 2024-11-27 → 2030-11-18 | Ouvrir |
| NCT06222788 Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer … |
Convertible Plasma Jet | Cancer | Non applicable | RECRUITING | En attente / non publié | Centre hospitalier de l'Universit… | Canada · Centre Hospitalier de l'Université de Montré… | 2025-04-07 → 2028-12 | Ouvrir |
| NCT07062536 mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Can… |
Oxaliplatin, 5FU, leucovorin | Cancer | Phase 2 | RECRUITING | En attente / non publié | Seoul National University Bundang… | South Korea · ASAN Medical Center, Seoul, South Korea… | 2025-08-27 → 2028-04-01 | Ouvrir |
| NCT07056946 Supra Inguinal Fascia Iliaca Block Versus Ultrasound-guided Caudal Anal… |
Supra Inguinal Fascia Iliaca Bloc… | Cancer | Non applicable | COMPLETED | En attente / non publié | National Cancer Institute, Egypt | Egypt · National Cancer institute, Cairo, Egypt | 2025-08-01 → 2026-08-01 | Ouvrir |
| NCT04776941 Expressive Writing for the Management of Stress in Cancer Survivors |
Expressive Writing for the Manage… | Cancer | Non applicable | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · M D Anderson Cancer Center, Houston, … | 2020-08-07 → 2028-12-31 | Ouvrir |
| NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telis… |
Telisotuzumab Adizutecan | Cancer | Phase 1/2 | RECRUITING | En attente / non publié | AbbVie | United States, Australia, Belgium, China, France, Ger… | 2025-03-06 → 2027-11 | Ouvrir |